4 pp. 157 kB

Little therapeutic progress was made in 2016, yet many medicines with no clinical value, uncertain efficacy or an unfavourable harm-benefit balance were authorised. This is due at least in part to the current system that drives pharmaceutical research and development. The primary focus is neither on patients’ needs nor on delivering genuine therapeutic advances at affordable prices.

(Visited 11 times, 1 visits today)
This entry was posted in Essential Medicines, General. Bookmark the permalink.
Facebook Auto Publish Powered By : XYZScripts.com
Get the latest issue of the NewsletterDownload